Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $94.0052W HIGH $309.35
Volume
536.02 K
Value Traded
322.84 M
Short % Float
6.29%
Days to Cover
1.6
+2.79%Week
-0.7%1 Month
+42.5%3 Month
+110.08%6 Month
-62.64%5 Year
+894.78%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
40.78 B
EPS (TTM)
5.46
P/E Ratio
49.42
Ent. Value
39.52 B
Total Shares
151.00 M
Float Shares
150.48 M
Insiders
0.34%
Institutions
114.54%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ILMN Catalyst Timeline
Dated clinical, regulatory and corporate events for Illumina, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Illumina, Inc.
346Total events
8Upcoming
79Tier-1 (high impact)
2020 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Product LaunchPost-Market
Early access availability of DRAGEN Ultra, BioInsight Platform Workflow Orchestrator, and Learning Cohorts
▲Product LaunchSpliceAI2Post-Market
Newly announced SpliceAI2 model for rare disease research
rare diseasesource ↗
▲Product LaunchPost-Market
Newly released DRAGEN v4.6 expands deployment options across cloud and CPU environments
▲Product LaunchPost-Market
Illumina launches BioInsight Platform, its first unified software environment
▲Platform ValidationSpliceAI2Preclinical
SpliceAI2 identified 17% more disease-relevant splice variants than other models in rare disease research dataset
rare disease researchsource ↗
▲PreprintSpliceAI2Presentation
Preprint released evaluating SpliceAI2 performance vs original SpliceAI and alternative splice prediction models
▲Partnership / LicenseCorporate
Billion Cell Atlas adds three new member companies including Formation Bio
▼IP Litigation RulingIP / Competition
German court rules Illumina infringes Element Biosciences patent on imaging method
▲Partnership / LicenseCorporate
Bifrost Biosystems secures commercial supply agreement with Illumina for SBS chemistry
◆Trial InitiationIlluminare-1Trial
Planned initiation of Phase 2 clinical trial of Illuminare-1 (rizedisben) in Breast Reconstruction
Breast Reconstructionsource ↗
▲Partnership / LicenseCorporate
IDT and Illumina announce strategic collaboration for DRAGEN secondary analysis pipeline on IDT xGen FFPE and cfDNA workflows
oncologysource ↗
◆Poster PresentationPresentation
Illumina and BMS present poster at ASCO 2026 on MRD solution
lung cancer (non-small cell metastatic)source ↗
◆Oral PresentationPresentation
Illumina to showcase fireflyGO with MiSeq i100 and Pillar oncoReveal panels at ASCO 2026
oncologysource ↗
▲Product LaunchfireflyGOPost-Market
Illumina and SPT Labtech launch fireflyGO automation platform
▲Product LaunchPost-Market
Illumina introduces first distributed WGS MRD research solution for early access
molecular residual disease (MRD)source ↗
▲Partnership / LicenseCorporate
Illumina and Labcorp expand collaboration to advance precision oncology testing
oncologysource ↗
▲PublicationPresentation
Publication in Frontiers of Oncology evaluating CGP in >7,600 NSCLC tumor samples
non-small cell lung cancersource ↗
▲Partnership / LicenseCorporate
Strategic collaboration with Veritas Genetics to form preventive genomics consortium
◆Manufacturing MilestoneCMC / Inspection
Rollout of new flow cells, staggered starts, and software enhancements
▲Partnership / LicenseCorporate
Illumina Laboratory Services to provide clinical sequencing and interpretation to IPRD Diagnostic Lab at FSU
rare diseasessource ↗
●Oral PresentationPresentation
Dr. Eric Green speaking at FSU for Rare Disease Day
rare diseasessource ↗
●Oral PresentationPresentation
Illumina unveiled new product updates and customer data at AGBT annual meeting
oncologysource ↗
◆Oral PresentationPresentation
Illumina management to present at investor conference fireside chat
▲Partnership / LicenseCorporate
Illumina and San Diego Zoo Wildlife Alliance partner to sequence Frozen Zoo samples
▲Partnership / LicenseCorporate
Alliance framework with AstraZeneca, Merck, and Eli Lilly as founding participants
●Oral PresentationPresentation
Illumina presentation at 44th Annual J.P. Morgan Healthcare Conference
▲Product LaunchPost-Market
CMS reimbursement granted for TruSight Oncology Comprehensive at $2,989.55 per test
solid tumorssource ↗
Past FDA Catalysts and PDUFA Decisions
How ILMN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 67%
Mid Cap(rank 441 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 18F-mFBG for administration Small moleculeNCT04535193 | Cardiovascular Diseases | Phase 1 | ACTIVE NOT_RECRUITING | 10 | Aug 30, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every ILMN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| advanced cancer | 2023-05-30 | improved survival in cancer patients who received CGP testing and targeted therapy compared to standard chemotherapyRead More | Real-world study data reveals better outcomes for cancer patients who receive comprehensive genomic testing Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced some of the latest data on the impact...Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Meister Keith A.Director | Sell | -7,500 882,351 held | $217.28 | 09/04/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ILMN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Casdin Capital, LLC | 4.7 % (-4.1 %) | 93.19 M | 530.00 K |
ILMN Institutional Ownership Trends
ILMN Short Interest
Shares sold short, counted twice a month.
6.29%
Short % of Float
of tradable shares sold short
9.5M
Shares Sold Short
-10.5% vs prior count
1.6 Low
Days to Cover
trading days of normal volume to buy every short share back
5.8M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ILMN ranks across every disease it competes in
Competitive Position is a premium feature
See how ILMN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialILMN News
ILMN▲ +5.6%on this news
Illumina BioInsight Platform expands with new software to accelerate the path from sequencing to discovery
Illumina has launched three early-access capabilities on its BioInsight Platform, including DRAGEN Ultra, Workflow Orchestrator, and Learning Cohorts. These tools aim to accelerate the transition from sequencing data to discovery by automating workflows and enhancing data analysis. The innovations support diverse research applications, including rare diseases and population genomics.
Read more →ILMN▲ +5.6%on this newsshared move
Illumina To Webcast Upcoming Investor Conference
Illumina, Inc. announced its participation in the UBS Global Healthcare Conference on November 10, 2026. The management team will engage in a fireside chat scheduled for 07:15am PT. Investors can access the webcast through Illumina's website, with a replay available for 30 days.
Read more →ILMNIllumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs
Illumina has launched the BioInsight Platform, a unified software environment aimed at transforming complex genomic and multiomic data into actionable insights. The platform integrates advanced analysis tools, AI innovations, and curated biological data, allowing researchers to streamline their workflows. Additionally, the latest DRAGEN update enhances accessibility for secondary analysis across various computing environments.
Read more →ILMN▲ +5.1%on this newsshared move
Illumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026
Illumina, Inc. has announced that it will release its third quarter 2026 financial results on October 29, 2026. Following the results, CEO Jacob Thaysen and CFO Ankur Dhingra will host a conference call to discuss the outcomes with analysts and investors. The call will be accessible via Illumina's website, with a replay available for 30 days post-event.
Read more →ILMNIllumina releases SpliceAI2 to help advance rare disease research
Illumina has launched SpliceAI2, a genomic AI model that enhances the identification of disease-relevant splice variants. Compared to previous models, SpliceAI2 identified 17% more relevant variants in rare disease research datasets. This advancement is part of Illumina's broader effort to improve genomic data interpretation and support researchers in understanding genetic variations. The model is now accessible through Illumina's BioInsight applications.
Read more →ILMNIllumina Reports Financial Results for Second Quarter of Fiscal Year 2026
Illumina, Inc. reported a revenue of $1.16 billion for Q2 2026, marking a 9.5% increase from Q2 2025. The company also raised its fiscal year guidance, anticipating total revenue between $4.60 billion and $4.64 billion. CEO Jacob Thaysen highlighted strong demand for their NovaSeq X technology, although operating margins showed a slight decline compared to the previous year.
Read more →ILMNIllumina expands Billion Cell Atlas program with new AI drug developers
Illumina has expanded its Billion Cell Atlas program by adding three new AI-driven drug developers, including Formation Bio. This collaboration aims to utilize Illumina's extensive genomic data to enhance drug discovery and development. The initiative is expected to help in identifying effective treatments and improving clinical trial designs, ultimately benefiting patient outcomes.
Read more →ILMNJuno Bio Opens First CLIA-Certified Sequencing Lab Dedicated Entirely to Women's Health, Backed by Ada Ventures, Artesian, Illumina Accelerator, and Entrepreneur First
Juno Bio has launched its first CLIA-certified sequencing lab focused on women's health, enhancing precision vaginal microbiome testing. The company secured $3.8 million in funding from notable investors to support this initiative. The lab aims to provide clinically actionable insights into vaginal health, addressing common but often misunderstood conditions. This development is expected to significantly improve care for women facing recurrent health issues.
Read more →ILMNElement Biosciences Prevails in German Patent Case Against Illumina
Element Biosciences has secured a favorable ruling from the Regional Court of Munich I, determining that Illumina infringed on its patent rights related to an imaging method for DNA sequencing. The court found both direct and indirect infringement by Illumina, which may impact their operations in Germany. This ruling strengthens Element's position in the competitive biopharma landscape.
Read more →ILMNIlluminare Biotechnologies Appoints Veteran Biopharmaceutical Leader as New CEO
Illuminare Biotechnologies has appointed Brian Longstreet as CEO, effective June 1, 2026. His extensive experience in the biopharmaceutical sector is expected to guide the company through its Phase 2/3 development and commercialization. The company is set to initiate a Phase 2 trial for its product, Illuminare-1, following positive Phase 1 results.
Read more →ILMNIllumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
Illumina, Inc. will release its second quarter 2026 financial results on July 30, 2026. Following the announcement, CEO Jacob Thaysen and CFO Ankur Dhingra will host a conference call to discuss the results. Interested parties can access the call via Illumina's website, with a replay available for 30 days post-event.
Read more →ILMNIllumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer
Illumina has appointed Mike Sullivan as Chief Commercial Officer and Julie Coletti as Chief Legal Officer, effective July 20 and August 3, 2026, respectively. These appointments are aimed at strengthening the company's leadership as it continues to advance its strategy in genomics and human health. Sullivan brings extensive experience in commercial leadership, while Coletti has a strong background in legal and regulatory affairs.
Read more →ILMNBifrost Biosystems Pens Agreement with Illumina for Supply of Sequencing Chemistry for Optical Pooled Screening Platform
Bifrost Biosystems has entered into a commercial supply agreement with Illumina to incorporate Illumina's sequencing-by-synthesis chemistry into its optical pooled screening platform. This collaboration aims to enhance the platform's capabilities, which will be available for commercial use in early 2027. The agreement ensures reliable access to essential sequencing technology for Bifrost.
Read more →ILMNDaniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors
Illumina, Inc. has appointed Daniel M. Skovronsky, MD, PhD, to its Board of Directors, effective June 16, 2026. Skovronsky, currently the Chief Scientific and Product Officer at Eli Lilly, brings significant experience in drug discovery and clinical development. His expertise is anticipated to bolster Illumina's capabilities in genomics and precision medicine.
Read more →ILMNIllumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution
Illumina launched the StrataMap Spatial Solution, a new end-to-end sequencing-based tool for spatial transcriptomics research. The technology provides single-cell resolution across a large capture area to map tissue structure and function. It detects twice as many unique genes per sample compared to probe-based alternatives. The system processes over 2000 samples annually and delivers results in under five days.
Read more →ILMNIntegrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster Insights
Integrated DNA Technologies (IDT) has announced a collaboration with Illumina to enhance oncology research workflows. This partnership integrates IDT's library preparation with Illumina's DRAGEN secondary analysis platform, aiming to streamline the process from sequencing to insights. The collaboration focuses on improving analysis for FFPE and cfDNA samples, ultimately supporting advancements in cancer research.
Read more →ILMN▲ +5.7%on this newsshared move
Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research
Illumina, Inc. has announced the launch of a new whole-genome sequencing solution aimed at molecular residual disease (MRD) research. This distributed kit will allow laboratories to more effectively adopt MRD detection protocols for clinical research. Currently in early access for select partners, the solution offers high analytical sensitivity and quick turnaround times, making it suitable for detecting early-stage tumors. Early evaluations, including studies at the Mayo Clinic, indicate strong concordance with previous clinical results, suggesting promising potential for wider clinical application.
Read more →ILMN▲ +5.7%on this newsshared move
Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research
Illumina and SPT Labtech have launched the fireflyGO automation platform, designed to streamline targeted oncology research. This new solution integrates with the MiSeq i100 Series, enhancing workflow efficiency and accessibility in genomic testing. The platform aims to reduce manual processes and improve turnaround times for cancer testing, while expanding Illumina's oncology research portfolio.
Read more →ILMNDavid P. King elected to Illumina's Board of Directors
Illumina, Inc. has announced the election of David P. King to its Board of Directors, effective immediately. King, the former Chairman and CEO of Labcorp, brings significant expertise in healthcare and diagnostics, which aligns with Illumina's goal of integrating genomics more deeply into standard healthcare practices. His leadership experience and knowledge in the industry is expected to bolster Illumina's clinical strategy and long-term impact on patients and shareholders. This change follows the retirement of three directors from the Board.
Read more →ILMNIllumina releases 2025 Corporate Responsibility Report, expanding access to genomics and accelerating global impact
Illumina Inc. has released its 2025 Corporate Responsibility Report, showcasing its efforts to enhance access to genomics and its sustainability initiatives. The report highlights partnerships aimed at population-scale genomics and the company's achievements in reducing environmental impact. Illumina's commitment to community engagement and innovation in genomic technologies is also emphasized.
Read more →About Illumina, Inc.
Headquarters5200 ILLUMINA WAY, SAN DIEGO, CA, 92122
BIOPHARMAWATCH ELITE PLUS
Trade the next ILMN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime